Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep;26(9):1872-1873.
doi: 10.1111/1756-185X.14654. Epub 2023 Mar 10.

Comment on: Successful treatment of rapid progressive interstitial lung disease in a case of anti-Zo antibody positive anti-synthetase syndrome

Haruka Koizumi  1 , Yoshinao Muro  1 , Satoshi Kamiya  1 , Norika Akashi  1 , Satoko Imai  1 , Yuta Yamashita  1 , Mariko Ogawa-Momohara  1 , Takuya Takeichi  1 , Masashi Akiyama  1
Affiliations
Editorial

Comment on: Successful treatment of rapid progressive interstitial lung disease in a case of anti-Zo antibody positive anti-synthetase syndrome

Haruka Koizumi et al. Int J Rheum Dis. 2023 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Li Y, Liu G, Yu F, Jiang Y. Successful treatment of rapid progressive interstitial lung disease in a case of anti-zo antibody positive anti-synthetase syndrome. Int J Rheum Dis. 2023;26(2):370-375. doi:10.1111/1756-185X.14471
    1. Tansley SL, Betteridge Z, Lu H, et al. The myositis clinical phenotype associated with anti-zo autoantibodies: a case series of nine UK patients. Rheumatology (Oxford). 2020;59(7):1626-1631. doi:10.1093/rheumatology/kez504
    1. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46(6):1005-1008. doi:10.1093/rheumatology/kem045
    1. Hamaguchi Y, Kuwana M, Takehara K. Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. Clin Rheumaotol. 2020;39(11):3489-3497. doi:10.1007/s10067-020-04973-0
    1. Tansley SL, Li D, Betteridge Z, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford). 2020;59(8):2109-2114. doi:10.1093/rheumatology/keaa021

LinkOut - more resources